ArticlePreventive medicine reports2026
Higher-order multiple primary cancers and persistent cross-site risk across human papillomavirus-related anatomical sites in the United States: a population-based Surveillance, Epidemiology, and End Results study.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preparing for the Era of Multiple Primary Cancers: A Prevention-Centered Model for Survivorship Medicine.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Survivors of cancers at human papillomavirus (HPV)-related sites are at increased risk of subsequent malignancies, but the burden and patterns of higher-order (≥3 primaries) multiple primary cancers (MPCs) and long-term cross-site risk patterns remain poorly understood. This study characterized these patterns and evaluated implications for cancer prevention and early detection. Methods: This population-based retrospective cohort study analyzed data from the United States Surveillance, Epidemiology, and End Results (SEER)-8, SEER-17, and SEER-21 registries from 1975 to 2022. We evaluated the incidence and distribution of MPCs as well as latency-specific standardized incidence ratios and cross-site associations across HPV-related sites. Results: Among 15.9 million cancer cases, 2.8 million (17.6%) were MPCs. Higher-order MPCs accounted for 4.1%-4.6% of diagnoses. Most HPV-related sites showed significantly elevated risk of higher-order MPCs, and the risk of MPCs persisted for ≥10 years of latency. Bidirectional cross-site associations included anus-to-tonsil and tongue-to-vulva associations at latency intervals of ≥10 years. Conclusions: Higher-order MPCs represent a substantial and underrecognized component of overall cancer burden. Survivors of cancers at HPV-related sites carry persistent, long-term cross-site risks. Current organ-specific follow-up strategies may be insufficient and suggest the need for more integrated, long-term surveillance and prevention strategies in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.